Expert hails new malaria drug approval for newborns as turning point for Africa
Switzerland’s recent approval of Coartem Baby, the first antimalarial treatment specifically designed for newborns and very young children, is a major step forward in tackling one of Africa’s most pressing public health challenges, says Dr Fortunate Mokoena, a malaria expert at the North-West University (NWU). Developed by Novartis with support from the non-profit Medicines for Malaria Venture (MMV), Coartem Baby is expected to be fast-tracked for approval in eight African countries that participated in the joint regulatory assessment.